{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:13:31Z","timestamp":1783653211745,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04887-6","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:34:37Z","timestamp":1779129277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-term treatment outcomes of the ranibizumab biosimilar CKD-701 for vitreous hemorrhage secondary to proliferative diabetic retinopathy"],"prefix":"10.1186","volume":"26","author":[{"given":"So Hyun","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaejin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"4887_CR1","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2015.15217","volume":"314","author":"JG Gross","year":"2015","unstructured":"Gross JG, Glassman AR, Jampol LM, et al. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2015;314:2137\u201346.","journal-title":"JAMA"},{"key":"4887_CR2","doi-asserted-by":"crossref","unstructured":"Sun JK, Glassman AR, Beaulieu WT et al. Rationale and application of the protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy. Ophthalmology. 2019;126:87\u201395.","DOI":"10.1016\/j.ophtha.2018.08.001"},{"key":"4887_CR3","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMp068185","volume":"355","author":"R Steinbrook","year":"2006","unstructured":"Steinbrook R. The price of sight\u2013ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355:1409\u201312.","journal-title":"N Engl J Med"},{"key":"4887_CR4","first-page":"Cd007419","volume":"2023","author":"G Virgili","year":"2023","unstructured":"Virgili G, Curran K, Lucenteforte E, et al. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2023;2023:Cd007419.","journal-title":"Cochrane Database Syst Rev"},{"key":"4887_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.survophthal.2024.03.009","volume":"69","author":"NM Bressler","year":"2024","unstructured":"Bressler NM, Kaiser PK, Do DV, et al. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review. Surv Ophthalmol. 2024;69:521\u201338.","journal-title":"Surv Ophthalmol"},{"key":"4887_CR6","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/s41433-019-0722-6","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Bandello F, et al. Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. Eye (Lond). 2020;34:1006\u20137.","journal-title":"Eye (Lond)"},{"key":"4887_CR7","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2147\/OPTH.S180393","volume":"12","author":"A Sharma","year":"2018","unstructured":"Sharma A, Reddy P, Kuppermann BD, et al. Biosimilars in ophthalmology: Is there a big change on the horizon? Clin Ophthalmol. 2018;12:2137\u201343.","journal-title":"Clin Ophthalmol"},{"key":"4887_CR8","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s40123-023-00715-y","volume":"12","author":"Y Yanagi","year":"2023","unstructured":"Yanagi Y, Takahashi K, Iida T, et al. Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan. Ophthalmol Ther. 2023;12:2005\u201321.","journal-title":"Ophthalmol Ther"},{"key":"4887_CR9","doi-asserted-by":"publisher","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939.","journal-title":"Semin Arthritis Rheum"},{"key":"4887_CR10","doi-asserted-by":"publisher","first-page":"e0275611","DOI":"10.1371\/journal.pone.0275611","volume":"17","author":"CK Yoon","year":"2022","unstructured":"Yoon CK, Oh J, Bae K, et al. Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial. PLoS ONE. 2022;17:e0275611.","journal-title":"PLoS ONE"},{"key":"4887_CR11","doi-asserted-by":"crossref","unstructured":"Sharma A, Holz FG, Kumar N et al. Biosimilar ranibizumab (Ranieyes) safety and efficacy in the real world: BRESER Study. J Vitreoretin Dis 2025:24741264251322213.","DOI":"10.1177\/24741264251322213"},{"key":"4887_CR12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1097\/IAE.0000000000001673","volume":"38","author":"E Chelala","year":"2018","unstructured":"Chelala E, Nehme J, El Rami H, et al. Efficacy of intravitreal ranibizumab injections in the treatment of vitreous hemorrhage related to proliferative diabetic retinopathy. Retina. 2018;38:1127\u201333.","journal-title":"Retina"},{"key":"4887_CR13","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1167\/iovs.05-0981","volume":"47","author":"K Schulze-Bonsel","year":"2006","unstructured":"Schulze-Bonsel K, Feltgen N, Burau H, et al. Visual acuities hand motion and counting fingers can be quantified with the freiburg visual acuity test. Invest Ophthalmol Vis Sci. 2006;47:1236\u201340.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4887_CR14","doi-asserted-by":"publisher","first-page":"e2244670","DOI":"10.1001\/jamanetworkopen.2022.44670","volume":"5","author":"DL Carl","year":"2022","unstructured":"Carl DL, Laube Y, Serra-Burriel M, et al. Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland. JAMA Netw Open. 2022;5:e2244670.","journal-title":"JAMA Netw Open"},{"key":"4887_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.4103\/ijo.IJO_2703_20","volume":"69","author":"JU Sheth","year":"2021","unstructured":"Sheth JU, Stewart MW, Khatri M, et al. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey. Indian J Ophthalmol. 2021;69:352\u20136.","journal-title":"Indian J Ophthalmol"},{"key":"4887_CR16","doi-asserted-by":"crossref","unstructured":"Shin G, Kim BS, Kim DY, Bae S. Unveiling the biosimilar paradox of oncologists\u2019 perceptions and hesitations in South Korea: a web-based survey study. BioDrugs. 2024;38:301\u2009\u2013\u200911.","DOI":"10.1007\/s40259-023-00640-3"},{"key":"4887_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/jamaophthalmol.2013.2015","volume":"131","author":"DRCR Network","year":"2013","unstructured":"Network DRCR. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol. 2013;131:283\u201393.","journal-title":"JAMA Ophthalmol"},{"key":"4887_CR18","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1001\/jama.2020.23027","volume":"324","author":"AN Antoszyk","year":"2020","unstructured":"Antoszyk AN, Glassman AR, Beaulieu WT, et al. Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2020;324:2383\u201395.","journal-title":"JAMA"},{"key":"4887_CR19","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1001\/jama.2020.22829","volume":"324","author":"GS Tan","year":"2020","unstructured":"Tan GS, Chakravarthy U, Wong TY. Anti-VEGF Therapy or Vitrectomy Surgery for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy. JAMA. 2020;324:2375\u20137.","journal-title":"JAMA"},{"key":"4887_CR20","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.2147\/OPTH.S419478","volume":"17","author":"MA Quiroz-Reyes","year":"2023","unstructured":"Quiroz-Reyes MA, Quiroz-Gonzalez EA, Quiroz-Gonzalez MA, Lima-G\u00f3mez V. Determining the Superiority of Vitrectomy vs Aflibercept for Treating Dense Diabetic Vitreous Hemorrhage: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Clin Ophthalmol. 2023;17:2359\u201370.","journal-title":"Clin Ophthalmol"},{"key":"4887_CR21","doi-asserted-by":"publisher","first-page":"e042484","DOI":"10.1136\/bmjopen-2020-042484","volume":"10","author":"HL Jeon","year":"2020","unstructured":"Jeon HL, Lee H, Yoon D, et al. Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis. BMJ Open. 2020;10:e042484.","journal-title":"BMJ Open"},{"key":"4887_CR22","doi-asserted-by":"crossref","unstructured":"Patel H, Allen A, Karl J et al. Diabetic retinopathy disease burden in patients with lower household incomes vs higher household incomes. J Vitreoretin Dis. 2025:24741264241309683.","DOI":"10.1177\/24741264241309683"},{"key":"4887_CR23","doi-asserted-by":"crossref","unstructured":"Gonzalez-Cortes JH, Martinez-Pacheco VA, Gonzalez-Cantu JE et al. Current treatments and innovations in diabetic retinopathy and diabetic macular edema. Pharmaceutics 2022;15.","DOI":"10.3390\/pharmaceutics15010122"},{"key":"4887_CR24","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/s41433-025-03732-2","volume":"39","author":"A Sharma","year":"2025","unstructured":"Sharma A, Woo SJ, Lee CS, et al. Aflibercept 2\u00a0mg biosimilars-will they lead the Anti-VEGF biosimilar world globally. Eye (Lond). 2025;39:1026\u20137.","journal-title":"Eye (Lond)"},{"key":"4887_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2025.2482663","volume":"25","author":"A Sharma","year":"2025","unstructured":"Sharma A, Woo SJ, Kuppermann BD. Aflibercept biosimilars - so near, yet so far. Expert Opin Biol Ther. 2025;25:1\u20133.","journal-title":"Expert Opin Biol Ther"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04887-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04887-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04887-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:20:26Z","timestamp":1783650026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04887-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4887"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04887-6","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Kim\u2019s Eye Hospital and was conducted in accordance with the tenets of the Declaration of Helsinki. Due to the retrospective nature of this study, the need for an informed consent was waived off (Kim\u2019s Eye Hospital IRB, Seoul, South Korea).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Consent for publication was not obtained since no identifying information of the participants was presented in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jae Hui Kim has received lecture fees from Bayer, Roche, Astellas, Samsung Bioepis, Samil Pharm. Co., Ltd., Chong Kun Dang Pharm. Co., Ltd., and Kukje Pharm. Co., Ltd. The other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"405"}}